Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Name: Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.
License: Public Domain

Fondazione IRCCS Policlinico San Matteo di Pavia

ClinicalTrials.gov · Datasets · License: Public Domain

lung cancer, lung cancer stage iii

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 674888
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.